leisure time -WSS

leisure time

author：Wikipedia 2025-10-02 00:29:19 - browse：999

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Scientists successfully use ultrasound imaging to map brain activity

focus

WSS

Lab trade group sues FDA to halt regulation of lab

First Opinion Podcast: What happens when kids become caregivers?

FDA's Pazdur wants cancer trials to range beyond China alone

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Let's speed up science by embracing open access publishing

Innovation in antibiotics is ailing. 'Brain drain' may kill it

hotspot

leisure time

leisure time

How one medical school became remarkably diverse

FDA's Pazdur wants cancer trials to range beyond China alone

Drug repurposing or repositioning? The language matters

Cord blood banking comes at a high cost to babies

Anesthesiologist group: stop taking Ozempic before surgery

See how much Covid

Cancer drug shortages should be causing more outrage

NIH documents show early flaws of $1.6 billion long Covid program

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Intellia reports positive results for its CRISPR

focus

ASCO: AstraZeneca says CAR

See how much Covid

Scientists successfully use ultrasound imaging to map brain activity

Dark money group runs ads on China biotech bill

David Sabatini, ex

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

hotspot

focus

Wikipedia

knowledge